.png)
Scientists at theUniversity of Colorado Anschutz have discovered that while brain neuron changes, including cell loss, may begin in early life, a drug long-approved for other conditions might be repurposed to slow this damage, offering new hope for those with Alzheimer’s disease (AD) and other cognition issues.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
A team of campus and system chief financial officers, representatives of the CU treasury and others is continuing its work to determine the impact of the financial market downturn and disconnects in information provided by […]
Trillion-dollar federal cuts will eliminate about $65 million annually by 2032. That’s almost the exact amount voters approved in a new tax in 2024. Click here to view original post Click Here to Publish/Feature Your […]
In its biggest investment so far, CordenPharma is earmarking €900 million ($982 million) over the next three years to expand its peptide platform capacity in the US and Europe to meet rising GLP-1 manufacturing demand. […]
Copyright © 2026 Biotech Networks
